CT Scans Boost Secondary Cancer Risk

New research indicates that patients with non-Hodgkin's lymphoma who undergo eight or more CT scans double their risk for secondary cancers.

Researchers from Taipei Veterans General Hospital in Taiwan found that these second cancers generally occurred in areas of the body where CT scan fields overlapped, amounting to double the radiation amount. These areas were where thoracic and abdominal CT scans overlap.

"The incidence of secondary-cancer origin from breast, stomach, and liver is higher in patients with more CT scans," wrote Sheng Hsuan Chien, MD, and colleagues from the Taipei Veterans General Hospital in Taiwan. "These sites are usually located at the interface or overlapping area and receive a double dose of radiation from 2-CT scans procedures."

The team looked at 4874 patients with non-Hodgkin's lymphoma who received curative-intent treatment from January 1997 to December 2010.

Patients had a median of eight CT scans done within one year of their diagnosis.

The risk is dose-dependent; therefore, with each additional CT scan, the risk for a secondary cancer went up by three percent.

"Physicians should assess the timing of CT scans more carefully and avoid [the overuse of] CT scans, especially in those with complete remission and a highly curable population," the researchers conclude.

Source: Medscape

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap